NO20030658L - Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner - Google Patents

Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner

Info

Publication number
NO20030658L
NO20030658L NO20030658A NO20030658A NO20030658L NO 20030658 L NO20030658 L NO 20030658L NO 20030658 A NO20030658 A NO 20030658A NO 20030658 A NO20030658 A NO 20030658A NO 20030658 L NO20030658 L NO 20030658L
Authority
NO
Norway
Prior art keywords
kinase proteins
lineage kinase
multiple lineage
investigation
modeling
Prior art date
Application number
NO20030658A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030658D0 (no
Inventor
Anna Maroney
Kevin M Walton
Craig A Dionne
Nicola Neff
Jr Ernest Knight
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20030658D0 publication Critical patent/NO20030658D0/no
Publication of NO20030658L publication Critical patent/NO20030658L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
NO20030658A 2000-08-11 2003-02-10 Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner NO20030658L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705400A 2000-08-11 2000-08-11
PCT/US2001/024822 WO2002014536A2 (en) 2000-08-11 2001-08-08 Odulating multiple lineage kinase proteins

Publications (2)

Publication Number Publication Date
NO20030658D0 NO20030658D0 (no) 2003-02-10
NO20030658L true NO20030658L (no) 2003-04-09

Family

ID=24554347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030658A NO20030658L (no) 2000-08-11 2003-02-10 Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner

Country Status (19)

Country Link
EP (1) EP1309721A2 (zh)
JP (1) JP2005503102A (zh)
CN (1) CN1458979A (zh)
AU (2) AU8317901A (zh)
BG (1) BG107623A (zh)
BR (1) BR0113266A (zh)
CA (1) CA2419985A1 (zh)
CZ (1) CZ2003680A3 (zh)
HR (1) HRP20030162A2 (zh)
HU (1) HUP0501110A3 (zh)
IL (1) IL154311A0 (zh)
IS (1) IS6711A (zh)
MX (1) MXPA03001218A (zh)
NO (1) NO20030658L (zh)
NZ (1) NZ524034A (zh)
PL (1) PL366248A1 (zh)
SK (1) SK2692003A3 (zh)
WO (1) WO2002014536A2 (zh)
ZA (1) ZA200301109B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO2005007144A2 (en) * 2003-07-14 2005-01-27 Decode Genetics Ehf Method of diagnosis and treatment for asthma based on haplotype association
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2014172616A2 (en) * 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
BR112019009711A2 (pt) * 2016-11-25 2019-08-13 Genuv Inc método de indução de neuro-regeneração, método de proteção de neurônios contra perda ou dano neuronal, método de prevenção ou tratamento de doença neurodegenerativa devido à perda ou dano neuronal, e método de triagem de candidatos de fármaco para o tratamento de doenças neurodegenerativas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
DK1105728T3 (da) * 1998-08-26 2005-08-08 Cephalon Inc Modulering af multiple lineage kinase-proteiner
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
ZA200301109B (en) 2004-07-20
EP1309721A2 (en) 2003-05-14
BR0113266A (pt) 2005-01-04
BG107623A (bg) 2003-11-28
CA2419985A1 (en) 2002-02-21
IL154311A0 (en) 2003-09-17
NZ524034A (en) 2006-11-30
SK2692003A3 (en) 2003-08-05
PL366248A1 (en) 2005-01-24
WO2002014536A2 (en) 2002-02-21
IS6711A (is) 2003-02-10
MXPA03001218A (es) 2003-05-27
CN1458979A (zh) 2003-11-26
HRP20030162A2 (en) 2005-12-31
AU8317901A (en) 2002-02-25
WO2002014536A9 (en) 2003-12-18
NO20030658D0 (no) 2003-02-10
HUP0501110A2 (en) 2006-03-28
JP2005503102A (ja) 2005-02-03
AU2001283179B2 (en) 2006-07-13
WO2002014536A3 (en) 2003-01-30
CZ2003680A3 (cs) 2003-11-12
HUP0501110A3 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
IS2142B (is) Nýtt form S-ómeprasóls
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
ATE172199T1 (de) Proteinkinase-c-inhibitor
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
DE60121953D1 (de) Herstellungsverfahren von arzneizubereitungen
DE69942264D1 (de) Hülse zum Einsetzen von chirurgischen Instrumenten
NO20020635L (no) Hemmere av proteinpolymeriserings og metodene som brukes
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO974453L (no) Proteinkinase C-hemmere
NO20032726D0 (no) Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling derav
NO995695D0 (no) Substituerte pyrazoler som p38-kinase-inhibitorer
IS6197A (is) Aðferð og búnaður til að koma lyfjablöndum á úðaform
NO20015797L (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
NO20002281D0 (no) FremgangsmÕte for generering av seismiske attributter
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE60210816D1 (de) Verfahren zur herstellung von 1-(carboxymethyl)-und 1(aminocarbonyl)-pyrimidin-4-on derivaten
NO20012014D0 (no) Blandinger av og fremgangsmåter for fremstilling av isotretinoin som har liten partikkelstörrelse
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
EE04154B1 (et) Omeprasooli valmistamise meetod
DE59813827D1 (de) Satz aus Prothesen unterschiedlicher Grösse
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
NO985248L (no) Indolylpyrrolydenmetylpyrrolderivater og fremgangsmÕte for deres fremstilli
NO20025069L (no) Ny stabil krystall av tiazolidindionderivat og fremgangsmÕte for fremstilling av det samme
NO20030658L (no) Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application